Insider Trading Wire
DOUGLAS BRATTON K, of Buys $15,000,000 Worth of $JUNO – #Form4 #InsiderTrading
On 12/24/14, DOUGLAS BRATTON K, reported a net BUY trade of JUNO with a net transaction amountof $15,000,000. Net non-zero shares traded: 625000. See below for more information on with symbol JUNO traded on the Nasdaq NM. Original SEC Filing Period of Report: 2014-12-23
The next big thing in oncology (JUNO )
Juno's lead candidate, JCAR015, is a treatment for acute lymphoblastic leukemia (ALL), the stellar results of which led the FDA to grant a breakthrough therapy designation last month, promising an expedited regulatory review
No offense doesn't matter what you think. Abbie is 12% cheaper than GILD. Black and white insurance Co going to OK Abbie drug and not GILD, that's what they do they will OK the cheaper drug and NOT ok the more expensive rug since they are both FDA approved.
Doesn't matter if it's one pill a day or 3- Doesn't matter which drugs, their all approved now. Insurance cares about only 1 thing and that's price. They will only OK the cheaper rug.
The Fly on The Wall
The "dramatic" increase in the beta-thalassemia patients' hemoglobin levels gives confidence that LentiGlobin will successfully treat sickle cell. Bluebird stands out from its peers because it is highly liquid and has a good chance of having a "transformational event," according to the analyst, who identified the stock as his top pick for 2015. Roth Capital analyst Debjit Chattopadhyay raised his price target on bluebird to $90 from $50. Noting that B-thalassemia patients currently have poor quality of life and die of the disease in their forties, the analyst wrote that Lentiglobin has "essentially cured" patients who had the disease. The data is "truly remarkable" and represents a "quantum leap," as it suggests that chronic diseases controlled by a single gene can be cured, Chattopadhyay wrote. Until now, doctors could only manage the symptoms of suchdiseases, the analyst indicated. Bluebird is "redefining healtcare," and B-thalassemia is just a start for the company, the analyst wrote.
Alibaba's Alipay assigned $70 billion valuation
By Jennifer Booton
Published: Dec 2, 2014 8:47 a.m. ET
NEW YORK (MarketWatch) -- Pacific Crest Securities outperform rating and $127 price target.
Do The DD Just Recently Leerink Raised Target LINK:
The Fly On The Wall
November 20, 201408:03 EDT AGIO Agios Pharmaceuticals price target raised to $124 from $90.
Leerink raised its price target for Agios Pharmaceuticals shares to $124 after the company presented initial data from AG-120 in acute myeloid leukemia that showed "robust activity." with solid tumor data on AG-120 and keeps an Outperform rating on the stock.
I'm out good luck